Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Cartesian Therapeutics reports significant improvement in myasthenia gravis patients, plans Phase 3 trial.

flag Cartesian Therapeutics reported positive results from a Phase 2b trial for Descartes-08, a treatment for myasthenia gravis, showing significant improvements in patients' daily living activities. flag Participants experienced a 5.5-point reduction in MG-ADL scores at four months, with responses lasting up to a year. flag The company's stock rose over 5% pre-market, and a Phase 3 study is planned for early 2025.

4 Articles

Further Reading